BCAX Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to Bicara Therapeutics's net margin of --. Bicara Therapeutics's return on equity of -- beat CEL-SCI's return on equity of --.

Bicara Therapeutics has a consensus price target of $39.44, signalling upside risk potential of 202.67%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 3372.22%. Given that CEL-SCI has higher upside potential than Bicara Therapeutics, analysts believe CEL-SCI is more attractive than Bicara Therapeutics.

Bicara Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.939%.

Bicara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicara Therapeutics pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Bicara Therapeutics quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Bicara Therapeutics's net income of -- is lower than CEL-SCI's net income of -$7.1M. Notably, Bicara Therapeutics's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicara Therapeutics is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Bicara Therapeutics's net margin of -711.67%. Bicara Therapeutics's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

Bicara Therapeutics has a consensus price target of $39.44, signalling upside risk potential of 202.67%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1259.65%. Given that IGC Pharma has higher upside potential than Bicara Therapeutics, analysts believe IGC Pharma is more attractive than Bicara Therapeutics.

Bicara Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.449, suggesting its more volatile than the S&P 500 by 44.948%.

Bicara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicara Therapeutics pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Bicara Therapeutics quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. Bicara Therapeutics's net income of -- is lower than IGC Pharma's net income of -$1.8M. Notably, Bicara Therapeutics's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicara Therapeutics is -- versus 16.76x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Bicara Therapeutics's net margin of -49.65%. Bicara Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Bicara Therapeutics has a consensus price target of $39.44, signalling upside risk potential of 202.67%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 45.3%. Given that Bicara Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Bicara Therapeutics is more attractive than NovaBay Pharmaceuticals.

Bicara Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Bicara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicara Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Bicara Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Bicara Therapeutics's net income of -- is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Bicara Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicara Therapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Bicara Therapeutics's net margin of 35.65%. Bicara Therapeutics's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

Bicara Therapeutics has a consensus price target of $39.44, signalling upside risk potential of 202.67%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 466.41%. Given that Protalix BioTherapeutics has higher upside potential than Bicara Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Bicara Therapeutics.

Bicara Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Bicara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicara Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Bicara Therapeutics quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Bicara Therapeutics's net income of -- is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Bicara Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 85.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicara Therapeutics is -- versus 3.98x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.